Compare Hut 8 Corp (HUT) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hut 8 Corp vs Neurocrine Biosciences Inc — how do they compare? Hut 8 Corp trades at $80.87 (market cap $9.82B), while Neurocrine Biosciences Inc trades at $142.61 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and Hut 8 Corp is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hut 8 Corp for 11 Days and Neurocrine Biosciences Inc for 23 Days on average.
| HUT | NBIX | |
|---|---|---|
Market Cap | $9.82B | $14.36B |
Volume | 10,272,678 | 1,237,180 |
Sector | Financials | Health |
52-Week High | $133.02 | $185.50 |
52-Week Low | $33.76 | $123.10 |
Typical Hold Time | 11 Days | 23 Days |
Enterprise Value | $17.25B | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HUT's stock trades at $80.25, down 10.13% over 24 hours, reflecting bearish technical signals amid weak financials. The company reported a net loss of $226.15 million for 2025, with negative cash flow from operations, though it secured a $1.07 billion credit facility to bolster liquidity. Analyst consensus remains strongly bullish with a $162.69 price target, driven by optimism around its AI infrastructure contracts.
The outlook hinges on HUT's ability to monetize its AI data center pipeline and achieve profitability. Key risks include persistent losses, high debt levels, and execution challenges in a competitive market. The stock offers high-reward potential if the company delivers on its growth strategy, but investors face significant downside if operational improvements falter.
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
